NASDAQ:ASND - Ascendis Pharma A/S
$71.53
 $1.00
+1.42%
1:45PM EDT
2019-02-15
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ASND     avg for
industry  
  avg for
sector  
42 stocks weight:  87. 17   0. 00   0. 00  
42 stocks rank:  2. 02 K 1. 86 K 1. 09 K
# analyst opinions:  9. 00   14. 92   14. 43  
mean recommendation:  1. 30   1. 91   1. 93  

quick ratio:  10. 14   5. 37   1. 81  
current ratio:  10. 54   5. 69   2. 19  

target price low:  74. 04   88. 97   117. 82  
target price avg:  84. 68   115. 19   141. 96  
target price high:  100. 69   143. 40   163. 16  
1-yr high:  76. 28   124. 30   142. 77  
last close:  70. 53   101. 85   127. 84  
50-day avg:  67. 25   98. 27   122. 46  
200-day avg:  66. 85   99. 72   122. 70  
1-yr low:  55. 16   78. 19   100. 16  
volume:  164. 24 K 2. 38 M 4. 64 M
50-day avg volume:  176. 51 K 3. 31 M 4. 94 M
200-day avg volume:  137. 64 K 3. 23 M 4. 28 M

1-day return:  0. 21 % 0. 22 % 0. 48 %
this week return:  3. 13 % 1. 77 % 2. 01 %
12-wk return:  19. 75 % 6. 56 % 3. 33 %
52-wk return:  25. 36 % -2. 23 % 14. 35 %

enterprise value (EV):  2. 88 B 55. 17 B 104. 51 B
market cap:  2. 96 B 49. 01 B 96. 46 B

shares outstanding:  42. 03 M 607. 99 M 1. 22 B
shares:  22. 53 M 605. 53 M 1. 15 B
shares short:  690. 36 K 11. 62 M 12. 55 M
shares short prior month:  668. 90 K 11. 95 M 13. 44 M
short ratio:  2. 71   4. 82   3. 10  

book value:  8. 43   14. 43   28. 26  
price/book:  8. 37   -1. 57   -2. 97  
gross profits:  1. 53 M 8. 28 B 18. 09 B
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  100. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -100. 00 % --- ---
1-yr mean volatility:  -0. 26 % 0. 01 % 0. 06 %

1-yr EPS:  -3. 87   3. 03   4. 09  
forward EPS:  -4. 37   4. 33   6. 99  
P/E:  -18. 22   6. 11   26. 91  
forward P/E:  -16. 11   8. 38   10. 48  
PE/G:  0. 19   0. 37   5. 61  
growth:  -95. 40 % 683. 72 % 104. 79 %
earnings high:  -0. 99   1. 27   1. 66  
earnings avg:  -1. 14   1. 01   1. 53  
earnings low:  -1. 30   0. 76   1. 40  
revenue high:  230. 00 K 2. 86 B 11. 19 B
revenue avg:  40. 00 K 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -33. 81 % -3. 27 % 3. 81 %
return on equity:  -52. 25 % 107. 48 % 27. 82 %
revenue growth:  -95. 40 % 648. 36 % 97. 70 %

beta (1yr vs S&P500):  1. 07   1. 21   0. 93  
sharpe (1yr):  -0. 60   0. 06   0. 98  

held % insiders:  22. 43 % 6. 46 % 3. 21 %
held % institutions:  47. 09 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ASND
.    + 4.527 =         4.527 :: INITIAL WEIGHT
.  + 149.903 =        154.43 :: inverse volume-to-price addition
.  + 310.902 =       465.332 :: spline projection addition
.  + 417.872 =       883.204 :: notable performance addition
.  - 105.926 =       777.278 :: poor performance penalty
.    x 1.373 =      1067.187 :: one-year gains+dividend factor
.    x 4.131 =      4408.814 :: 13 weeks' performance factor
.    x 1.492 =      6580.106 :: industry recommendation factor
.    x 3.399 =      22367.37 :: symbol recommendation factor
.    x 0.997 =      22291.74 :: return on assets factor
.    x 0.995 =     22175.258 :: return on equity factor
.     x 0.99 =     21963.707 :: revenue growth factor
.    x 2.149 =      47203.05 :: current ratio factor
.    x 1.053 =     49718.531 :: quick ratio factor
.     x 1.17 =     58172.884 :: short ratio factor
.    x 2.173 =    126405.822 :: price-to-book factor
.    x 1.041 =    131620.931 :: 5-day avg > 200-day avg
.    x 1.035 =    136238.073 :: 5-day avg > 50-day avg
.    x 1.006 =    137051.199 :: 50-day avg > 200-day avg
.    x 2.047 =    280507.009 :: P/E weight
.    x 1.513 =    424319.639 :: PE/G factor
.    x 1.647 =    698809.467 :: beta factor
.    x 0.604 =    422236.707 :: sharpe factor
.    x 1.222 =    515891.167 :: target low factor
.    x 1.149 =    592915.531 :: target mean factor
.    x 1.065 =    631687.829 :: target high factor
.    x 1.066 =    673134.641 :: industry 12-weeks return
.    x 0.997 =    670816.124 :: "drift" penalty 3 days ago
.      x 1.0 =    670642.431 :: overall "drift" factor
.    x 0.891 =    597450.484 :: largest single-day jump factor
.     x 1.01 =     603409.27 :: mean volatility factor
.    x 1.098 =    662385.027 :: 42-day mean volatility factor
.      x 1.0 =    662429.488 :: factor hist industry gain for week 06
.   cubeRoot =        87.173 :: reduced for readability
.                     87.173 :: FINAL WEIGHT for NASDAQ:ASND


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org